An interventional study of Biodegradable occluder and Metal occluder in PFO - Patent Foramen Ovale, Migraine and Migraine Headache, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Foramen Ovale, Patent with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Foramen Ovale, Patent · China.
Among the 20 studies in Foramen Ovale, Patent with a site in China, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 13th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →13 of the 20 studies in Foramen Ovale, Patent with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–60
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–60
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–65
Peking University Third Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 154 across 69 interventional studies indexed under Foramen Ovale, Patent.
Median enrollment 211 across the 14 interventional studies, 565 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Chinese Academy of Medical Sciences, Fuwai Hospital has 4 studies filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
4 of the studies in Foramen Ovale, Patent with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
| NCT07170176First Affiliated Hospital Xi'an Jiaotong UniversityEffects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine | 2027-05-31 |
| NCT06863350Sichuan UniversityPercutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale(PREDICT-PFO Trial) | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Foramen Ovale, Patent with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults. Mechanisms linking PFO to migraine include cortical spreading depression, vascular active substance theory, impaired cerebral autoregulation, and genetic susceptibility. Understanding these mechanisms holds promise for overcoming challenges in the prevention and treatment of migraines in PFO patients. At least 11 observational studies, comprising 1,632 subjects, described the efficacy of PFO closure in cryptogenic stroke. Of these, 34% had migraines, and percutaneous PFO closure reportedly reduced migraine days by 81% (with a reduction of over 50% in monthly migraine days). Prospective randomized controlled trials (PRIMA and PREMIUM trials) assessing the Amplatzer® PFO Occluder showed significant benefits in most secondary endpoints, with a pooled analysis indicating its safety and effectiveness compared to medical therapy.While traditional metal PFO closure studies suggest symptom relief, reports also mention potential new-onset or worsened migraines post-closure. Proposed mechanisms include platelet activation, microthrombus formation, nickel allergy, and septal deformation or stretching inducing the release of migraine-related vascular active substances. However, these theories are closely tied to the presence of permanent metal implants.
Addressing these concerns, the MemoSorb® biodegradable PFO Occluder system, approved by the National Medical Products Administration (NMPA) in September 2023, offers an innovative solution. Developed collaboratively by the National Biomedical Materials Engineering Technology Research Center, Professor Wang Yunbing\'s team, Professor Pan Xiangbin\'s team from Fuwai Hospital, Chinese Academy of Medical Sciences, and HeartTech Medical, this groundbreaking technology represents a shift from metal to degradable materials. The occluder serves as a temporary bridge post-implantation, gradually degrading with endothelialization, facilitating comprehensive self-repair. This intervention concept theoretically avoids the lifelong complications associated with traditional metal occluders, effectively reducing postoperative symptoms like migraines and dizziness.
To assess and compare the treatment outcomes, especially in relieving migraines, a prospective, single-blind, randomized controlled study has been designed for patients with patent foramen ovale and migraine, comparing the novel biodegradable occluder with the metal occluder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Biodegradable occluder
Device: Metal occluder
Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
Patients assigned in this group will receive metal occluder for PFO occlusion
Reduced days per month at 12 month's follow-up
In the 12th month of follow-up, the average reduction in migraine days per month
Time frame: 12 months
Plan to share: Undecided
Started Mar 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.
Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences, Fuwai Hospital →